E

Exploring the immunological links between lung cancer and Covid–19

Some immune cells overlap in cancer and Covid-19 so what can we learn from them in order to make an impact?

March 31, 2020
E

Insights of the Decade

The December 17, 2010 issue of "Science" has the catchy of title of "Insights of the Decade", one of which is the ubiquitous role of inflammation in multiple chronic illnesses including cancer.

January 3, 2011
E

The Best Clinical Data at SITC wasn’t NextCure’s NC318 Siglec–15

Analysis and commentary of Nektar's IL-2 cytokine bempeg in combination with nivolumab in 1L advanced melanoma

November 11, 2019
E

Waves and waves of T cells

What can we learn from biomarkers and immune profiling in patients receiving bempeg, a CD122-directed pegylated IL-2 therapy

June 27, 2019
E

Navigating new opportunities in the IL-2 space

How is Synthorx's IL-2 cytokine THOR-707 different from other compounds in this niche?

June 26, 2019
E

How failure allows us to continually innovate

How the design of different cancer approaches can affect clinical performance

June 24, 2019
E

Alternative approaches to targeting cytokines

Can we employ red blood cells in allogeneic, off-the-shelf cellular therapy products for the treatment of cancer?

June 19, 2019
E

New developments in cytokines as immune modulators

New insights emerging from research on cytokines as an effective way to induce anti tumour immunity

January 31, 2019
E

Pinning down potential new opportunities for IL–8 and 4–1BB

What is old is new again - a look at some forgotten oncology targets that are coming back in fashion

November 13, 2018
E

An analysis of Nektar’s latest PIVOT data and pipeline update

Update on PIVOT-02 with nivolumab plus NKTR-214 in 1L metastatic melanoma

November 12, 2018
E

Learnings from IO combinations and where we’re headed

Lessons learned from recent failure and a look at where a few new developments might be coming from...

August 23, 2018
E

Armored CAR-T cell therapies and commercial threats from the East

On launched products, armored CARs and the potential threat from China

August 16, 2018
E

In a Prudential Light

Bringing together disparate notes on cytokines and how they can be useful as an immunotherapy partner.

June 19, 2018
E

The Potential for Cytokines in Cancer Immunotherapy

The latest part in our cytokine mini-series explores the potential for incorporating them in CARs or combining with checkpoint blockade through the lens of an expert in the field...

June 18, 2018
E

How should we interpret the NKTR–214 data presented at ASCO?

What can we learn from the updated Nektar NKTR-214 data presented at #ASCO18?

June 14, 2018
E

Stacking up evidence from IO clinical trials

A look at various lessons from recent IO trials and how they can applied to new readouts expected at ASCO18

May 3, 2018
E

Bench to bedside and back again

A look at how basic and translational evidence points towards TGFβ as a possible new target for IO combos in some tumour types

May 1, 2018
E

Targeting TGF-β and the tumour microenvironment

A look at one way with which we can target the tumour microenviroment to improve response of cancer immunotherapy

April 30, 2018
E

Targeting NK cells effectively in AML

A look at targeting NK cells with immune agonists, cytokines and adoptive cell therapies

March 14, 2018
E

Update on cytokines as novel cancer immunotherapy

A look at innate approaches to stimulating the immune system including IL-15 agonists

February 21, 2018
E

Nektar hits it out of the park at SITC 2017

A look at Nektar's promising IO portfolio and what's next for the up and coming biotech

November 13, 2017
E
National Harbor from Gaylord Hotel

SITC17 – Final Look at what to watch out for

Final SITC17 Preview and a look at key talks now that the abstracts are available.

November 8, 2017
E

A look at Nektar Therapeutics immunotherapy pipeline

Update on Nektar Therapeutics IO portfolio and a look at their burgeoning autoimmune disorder pipeline

July 24, 2017
E

SITC 2016 Can Nektar Boost Checkpoint Performance

Without effector T cells in the tumour, checkpoints won't work. So how do we attract more in? Here's one way to do it...

November 16, 2016